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Neal S. Young,1 Andrea Bacigalupo,2 Judith C. W. Marsh3An immune basis for most patients with aplastic anemia (AA) provides a rationale for immunosuppressive
therapy (IST), using antithmyocyte globulin and cyclosporine as one therapeutic modality; hematologic re-
sponse is observed in up to 75% of patients. Recent advances in understanding the pathogenesis of AA
have identified defective telomere maintenance as an important explanation for the onset of marrow failure,
relapse and clonal evolution after IST, in some patients with AA. The finding of inherited mutations in the
telomerase gene complex in patients with apparent acquired AA has important implications for clinical man-
agement. Hematopoietic stem cell transplantation (HSCT) for acquired AA, whether from an HLA identical
sibling or an unrelated donor, provides an excellent chance of long term cure. Current issues with HSCT
include graft rejection, chronic GVHD and poor outcome in older patients. The lack of a suitable bone mar-
row donor for all patients who need a transplant, illustrates the need for novel transplant procedures, such as
cord blood transplantation.
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PATHOPHYSIOLOGYOF IMMUNE-MEDIATED
MARROW FAILURE: NEAL S. YOUNG
The last several years have seen exciting develop-
ments in the study of bone marrow (BM) failure. In
the clinic, outcomes for older patients undergoing
allogeneic sibling transplant and younger patients
receiving hematopoietic stem cells from matched un-
related BM donors have markedly improved [1-4]. In
patients who are treated with immunosuppression,
overall hematologic improvement has been increased
with tandem courses of antithymocyte globulin
(ATG), and survival in primary refractory patients
has increased, because of both more aggressive immu-
nosuppression and supportive care, especially new an-
tifungal agents [5-7]. In the laboratory, sophisticated
flow cytometry and molecular biology methods allow
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can be assessed early by sensitive techniques like fluo-
rescein in situ hybridization (FISH) and the applica-
tion of genomics, as in comparative genomic
hybridization (CGH). Finally, discoveries in the BM
failure clinic have been generalized to the origins of
a broad group of human cancers and to specific organ
failure disease. The linking of constitutional BM fail-
ure to acquired aplastic anemia (AA) through genetic
defects in telomere repair has provided the likely
explanation for the troubling evolution from an in-
flammatory pathophysiology, T cell-mediated BM
destruction, to malignant hematologic diseases like
myelodysplastic syndrome (MDS) and acute myeloge-
nous leukemia (AML). The regenerative/repair deficit
conferred by telomerase deficiency affects not only BM
but other tissues, leading to disease in the lung and
liver.
Whatever their long-term outcome in the clinic,
that the great majority of patients with AA will re-
spond to immunosuppressive therapy (usually deliv-
ered as at least 1 and sometimes 2 repeated course
of ATG) implies an underlying immune pathophysi-
ology. Low pretreatment blood counts (reticulocytes
and lymphocytes) decrease the probability of hemato-
logic improvement after immunosuppression and of
survival, suggesting that stem cell number (rather
than an alternative pathophysiology) limits response
to therapy [7]. The persistence of oligoclones of cyto-
toxic T cells after successful ATG administration,
their reemergence at relapse, and uncertainty as
to the mechanism(s) of action of ATG, can beS119
Figure 1. Survival up to 10 years for patients (n5 2400) with SAA
treated with ATG reported to the EBMT database having received
ATG6CSA as a first-line treatment. Patients were treated between
1973 and 2007. Five-year survival probabilities are: 49%6 7% for patients
treated between 1973 and 1980 (n5 178), 62%6 3% for those treated
between 1980 and 1990 (n5 850), 74% 6 3% for patients treated be-
tween 1990 and 2000 (n5 928), and 72% 6 6% for those treated
between 2000 and 2007 (n5 444). From [13], with permission.
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immune therapeutic strategies.
Clonal evolution occurs in a subset of patients,
about 15% long term, and is almost always manifest
as the emergence of aneuploidy in BM cytogenetics,
accompanied by recurrent pancytopenia and often
MDS or leukemia [8,9]. Selection of clones is broadly
understood from in vitro and in vivo studies. For the
most common abnormality of monosomy 7, in AA,
as also in congenital neutropenia, elevated granulo-
cyte-colony stimulating factor (G-CSF), either endog-
enous in the setting of severe neutropenia or
exogenous because of chronic administration of the
cytokine, favors cells bearing a G-CSF receptor that
signals for proliferation and not differentiation [10].
For trisomy 8, an immune response to aneuploid cells
leads to selection and persistence of trisomy 8 cells that
fail to complete apoptosis.
Defective telomere homeostasis is a feature of AA
in some cases, and helps explain the occurrence of mar-
row BM failure, relapse, and clonal evolution. Muta-
tions in genes of the telomere repair complex and of
the shelterin proteins occur in children with dyskera-
tosis congenita; mutations in TERT (the telomerase
gene), TERC (the RNA template gene), and also in
TINF2 (a shelterin gene) are also present in adults
without obvious family histories and in the absence
of typical physical findings associated with constitu-
tional BM failure [11,12]. TERT and TERC mutations
reduce telomerase activity in vitro and accelerate telo-
mere attrition in vivo. TERT mutations subsequently
have been associated with idiopathic pulmonary fibro-
sis. Most recently, we have studied 5 families in which
the probands presented with BM failure, and TERT
and TERC mutations in these pedigrees have tracked
with severe liver disease; telomerase repair mutations
also have been detected in a large series of patients
with a variety of liver diseases. Abnormal telomere bi-
ology underlies regenerative diseases of BM, lung, and
liver.
In acquired AA, independent of known genetic al-
terations, the presence of short telomeres of leukocytes
at time of presentation profoundly affects the clinical
course: patients with short telomeres do respond to im-
munosuppressive interventions, but their relapse rate is
almost double that of cases with normal telomere
length, and virtually all clonal evolution occurs in pa-
tients in the lowest quartile of telomere length. Excess
telomere-free ends of chromosomes and genomic in-
stability by spectrakaryotyping (SKY) can be demon-
strated in tissue culture of BM from AA patients with
short telomeres and TERT- and TERC-mutant family
members. Hypomorphic TERT mutations can also be
detected in patients with de novo AML. These data in
patients and with human cells confirm predictions
made based on yeast experiments and in ‘‘knock-outs’’
of telomerase genes in the mouse. Short telomeresand single nucleotide polymorphisms in TERT have
been linked bymultiple laboratories to cancer develop-
ment in other circumstances, suggesting that telomere
biology provides the missing link between chronic
inflammation and malignant transformation. In BM
failure, sex hormone therapymay be helpful in improv-
ing hematopoiesis because of direct modulation of
telomerase activity.OUTCOMES AFTER IMMUNOSUPPRESSIVE
THERAPY FOR APLASTIC ANEMIA: JUDITH
C.W. MARSH
Introduction
The current standard immunosuppressive therapy
(IST) for AA is the combination of ATG and cyclo-
sporine (CsA). Overall survival (OS) after IST for AA
has improved significantly during the period from
the early 1970s to 2000, and is currently around 75%
at 5 years. Although this equates with survival after he-
matopoietic stem cell transplantation (HSCT), there
are important differences between IST and HSCT
for AA in terms of speed of hematologic recovery, later
complications, and quality-of-life issues. Survival fol-
lowing IST has, however, failed to improve further
during the last decade (see Figure 1) [13].
Indications for IST
ATG with CsA is indicated as first-line therapy for
nonsevere AA patients who are transfusion dependent,
severe AA (SAA) patients .40 years of age, and SAA
patients\40 years who lack an HLA-identical sibling
donor. Patients with SAA who are\40 years old and
Figure 2. Treatment of acquired SAA. CRP, clinical research protocol; IST, immunosupressive therapy; UCB, umbilical cord blood; MUD, matched un-
related donor; CsA, cyclosporine; HLA id sib., HLA-identical sibling. *For patients older than 60 years, there is currently insufficient data on the role of
HSCT in SAA, although data for MDS suggests that this may be a future option (see text). With permission from [14].
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fered HSCT as first-line treatment. In Europe, unre-
lated donor (UD) HSCT is now considered after
failure to respond to 1 course of ATG in patients
who lack an HLA-compatible sibling (see Figure 2),
as a result of recent improvements in outcome after
UD HSCT [14]. Older age is not per se a reason for
withholding specific treatment, but depends on sever-
ity of the disease, and mainly on the severity of neutro-
penia, the presence of comorbidity, and the willingness
of the patient and his family to be treated, as patients
.60 years old have an increased risk of infection,
bleeding, and cardiac events after ATG [15].Response Rates and Predictive Factors after
ATG and CsA
Response to ATG occurs in around 50% by 3
months and 70% to 75% by 6 months, and supports
an autoimmune basis for the disease in many patients.
Lack of response may be because of (1) inadequate im-
munosuppression, (2) irreversible stem cell deficiency,
or (3) nonimmune-mediated AA. Patients with nonse-
vere AA are more likely to respond than patients with
SAA or very severe AA. However, the classical Camitta
criteria do not reliably predict for response to ATG, as
they were established in the pre-ATG era to assess who
may benefit from HSCT. Recent work has shown that
only younger age, absolute reticulocyte count (ARC)
and absolute lymphocyte count (ALC), correlate with
response to ATG [7]. The lack of association with the
absolute neutrophil response reflected a high number
of early deaths in patients with very severe neutropenia.
Several studies have examined whether the presence ofa PNH clone is associated with response to ATG,
with conflicting results. This may reflect differences in
sensitivity of the test used to detect a paroxysmal
nocturnal hemoglobinuria (PNH) clone. Using very
sensitive tests to detect glycosylphosphatidylinositol
(GPI)-deficient clones of\0.003 cells, a strong correla-
tion exists with response among Japanese patients [16].
Shortened telomere length (which occurs in around
a third ofAApatients) does not preclude initial response
to IST, but predicts relapse after ATG and is a risk
factor for later cytogenetic abnormalities and evolution
to MDS and AML [17].Can Response to ATG and CsA Be Improved
Further?
Two prospective randomized studies have exam-
ined the use of daily G-CSF for 3 months after ATG
and CsA [18]. The addition of G-CSF conferred no
benefit in terms of survival, durable response, or reduc-
tion in infections. Follow-up was too short to evaluate
the long-term risk of clonal evolution to MDS, AML,
or PNH. A retrospective study from the European
Blood and Marrow Transplant (EBMT) showed
a trend for more MDS/AML when G-CSF is used
with ATG and CSA, and G-CSF was a significant
risk factor forMDS/AML in older patients (.40 years)
[9]. In vitro studies have shown that G-CSF causes
expansion of small preexisting monosomy 7 cells and
upregulation of the isoform IV G-CSF receptor,
resulting in defective differentiation signaling and
expansion of undifferentiated cells [10].
The rationale for using additional immunosup-
pressive agents with ATG and CsA is that the
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insufficient immunosuppression for some patients. A
retrospective study showed no improvement in re-
sponse or reduction in relapse using mycophenolate
mofetil (MMF) in combination with ATG and CsA
compared to without MMF [19]. The addition of siro-
limus in a prospective randomized study resulted in no
significant difference in response to ATG and CsA
(51% at 6 months in the arm with sirolimus and 62%
without sirolimus) [20].
A second course of ATG may be given if there is
relapse after the first course or no response to the first
course. When rabbit ATG is given for the second
course following an initial course of horse ATG, the
response rate was 30% for nonresponders and 65%
for relapsing patients [21]. A recent study from Japan
has examined prospectively the outcome of 52 children
who failed 1 course of IST. The response to a second
course of ATG was only 11%.Alternative Immunosuppressive Agents
High-dose cyclophosphamide (Cy) (200 mg/kg)
given in the absence of stem cell support, results in du-
rable responses, and were seen in just over 50% of pa-
tients who have failed ATG, but the predictable and
markedly prolonged cytopenias exposes patients to
a high risk of fatal fungal infections, and prolonged
in-patient days in hospital. Furthermore, it does not
eliminate the risk of clonal events. The anti-CD52
monoclonal antibody (mAb), alemtuzumab is cur-
rently being evaluated in the treatment of AA. A small
prospective study using a single course of alemtuzu-
mab (100 mg over 5 days) and CsA in AA, showed re-
sponse in 9 of 18 patients. Relapses were common but
successfully treated with a further course [22]. Dacli-
zumab (anti-IL-2R) shows response in almost 40%
of patients with nonsevere AA [6].Late Complications after IST
Relapse occurs in up to 30% to 35% of patients
when CsA is withdrawn at 6 months. A more pro-
longed course of CSA with a later slow tapering of
the drug reduces the relapse risk to around 13% to
16%, and about a third of patients are CsA dependent
and required a small dose long term. Long-term
follow-up of the prospective German national study
of 84 patients treated with either the combination of
ATG and CSA or ATG alone, between 1986 and
1989, reported an actuarial probability of developing
hemolytic PNH at 11 years of 10%, MDS or AML
8%, and a solid tumor 11% [8]. Risk factors for devel-
oping MDS/AML include (1) repeated courses of
ATG, (2) older age, (3) high doses and prolonged du-
ration of G-CSF with ATG and CsA, and (4) short
telomeres.BONE MARROW TRANSPLANTATION (BMT):
ANDREA BACIGALUPO
HLA identical siblings
Current outcomes
An allogeneic bonemarrow transplant (BMT) from
an HLA-identical sibling remains the treatment of
choice for patientswith acquired SAA.The current sur-
vival for children (\16 years) receiving a BMT from an
HLA-identical sibling, following a preparative regi-
men with Cy 200 mg/kg, is 91%, significantly better
than survival for patients over 16 years of age (74%)
[2]. As to the stem cell source, a recent EBMT/Interna-
tional BoneMarrowTransplant Registry (IBMTR) re-
port suggests that the use of peripheral blood (PB)
reduces survival when compared to BM, in patients
\20 years, from85% to 73%, and in patients.20 years
from 64% to 52%: the major cause of excess mortality
in the PB arm was chronic graft-versus-host disease
(cGVHD) [23].This study suggests that PB transplants
should not be used in patients with acquired AA, possi-
bly because the increased incidence of cGVHD does
not translate in improved survival in AA patients, in
the way it does benefit patients with leukemia. A suit-
able BM cell dose is recommended, because results of
transplantation are highly dependent on the number
of nucleated cells infused. Cy alone remains the best
conditioning regimen for young patients, and ATG
would seem to reduce the risk of graft failure, although
a recent randomized trial has shown some advantage,
but no significant difference in survival [24]. The com-
bination of CsA and methotrexate (MTX) offers a sur-
vival advantage over CsA alone (84% versus 75%),
when used for GVHD prophylaxis. Therefore, stan-
dard Cy 50 mg/kg/day 4, with 3 days of ATG condi-
tioning, followed by unmanipulated BM as a stem cell
source, and CsA1MTX as GVHD prophylaxis is still
standard of care for patients with acquired AA under-
going an HLA-identical sibling transplant.
Irradiation
In the recent EBMT analysis of SAA patients
undergoing an HLA identical sibling BMT, the use
of irradiation was a significant negative predictor for
outcome [2]. Although some centers continue to use
total lymphoid irradiation (TLI) for HLA-matched
sibling transplants, with excellent results and no sec-
ond tumors, the consensus in the EBMT Working
Party is that, in the setting of an HLA identical sibling
transplants, the use of irradiation, PB, or other condi-
tioning regimens should all be tested in prospective
trials, because of an unproved benefit for the patient.
HLA identical BMT for patients over 30 years
Despite the excellent results with standard BMT in
AA (see Figure 3), there is a strong age effect: the
Figure 3. Acturial survival of SAA paitents undergoing a BMT from
HLA-identical siblings or from alternative donors. In the periods 1991
to 1996, the difference in acturial survival is .35%. In the period 1997
to 2002, the difference is reduced to \15% (data from the EBMT
WPSAA).
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HLA identical siblings in the last decade is respectively
83% , 73%, 68%, and 51% for patients aged 1 to 20
years (n5 681), 21 to 30 years (n5 339), 31 to 40 years
(n5 146), and $40 years (n5 111) (EBMT data un-
published). Unfortunately, the use of PB as a stem
cell source did not solve the problem, and actually
worsened outcome in older patients, although not sig-
nificantly [23]. There have been 3 reports in the liter-
ature suggesting that the combination of fludarabine
and Cy (Flu-Cy) produces a high rate of engraftmentand very encouraging survival [25]. We have therefore
explored the use of Flu-Cy and ATG, in patients over
the age of 30: the initial results are encouraging. with
transplant mortality lower than 30%; we have also
compared the Flu-Cy regimen given to 30 patients
(median age 45) with a matched pair of SAA patients
receiving Cy 200 (median age 39): actuarial survival
at 5 years was 76% for Flu-Cy versus 56% for Cy200
(EBMT data unpublished).
Engraftment, rejection, mixed chimerism
One of the historic issues in SAA transplants has
always been engraftment/rejection, the reason being
that (1) this is an autoimmune disorder, and (2) Cy
200 alone is not immunoablative. Rejection is re-
ported in the range of 1% to 25%, according to the
conditioning regimen and the duration of transfusion
support before transplant. In some countries, where
patients are highly sensitized, busulfan (Bu) has been
introduced in the conditioning regimen. There are
several forms of rejection: (1) failure to achieve a neu-
trophil count of 500/cmm (so-called primary graft fail-
ure or failure to engraft); (2) acute/early rejection after
initial engraftment (classic early rejection); (3) late, of-
ten progressive, graft failure; and (4 acute rejection
following discontinuation of CSA therapy: the 3 latter
are referred to as secondary graft failure.The Center for
International Blood and Marrow Transplant Research
(CIBMTR) has recently analyzed 166 patients receiv-
ing a second graft from sibling donors, to study risk
factors affecting outcome [26]: best survival was seen
in patients with good performance status grafted be-
yond 3 months from first transplant (76%) compared
to 33% for patients with poor performance status
grafted within 3 months from first transplant. The
predominant cause of failure was nonengraftment.
The conclusion of this study is that novel condition-
ing regimens should be investigated for second trans-
plants in SAA patients with primary or secondary graft
failure [26].
With improved methods to identify donor/recipi-
ent cells, we have learned that many patients have
mixed chimerism posttransplant. A recent EBMT
analysis stratifies patients into 5 separate groups: (1)
complete donor chimerism, (2) transient mixed chi-
meras, (3) stable mixed chimeras, (4) progressive mixed
chimeras, and (5) recipient cells and early rejection
[27]. The complete donor chimeras have more
GVHD, whereas progressive mixed chimeras are at
high risk of late graft failure, especially after discontin-
uation of CSA therapy. Therefore, monitoring chime-
ric status after transplantation in SAA is important, and
may give relevant information on optimal immuno-
suppressive therapy to be administered: a significant
proportion of patients (approximately 30%) will be-
come permanent mixed chimeras, with normal cell
counts and usually no GVHD.
S124 Biol Blood Marrow Transplant 16:S119-S125, 2010N. S. Young et al.UD Transplants
The outcome of unrelated donor transplants for
patients with AA has improved in the last decade [28]
(see Figure 3): better donor/recipient HLA matching
has probably played a major role, but also significant
changes in the conditioning regimen have occurred
[29,30]. The Japanese study reported 154 SAA patients
undergoing an UD transplant, the majority receiving
3 Gy TBI [30]: unfavorable factors for survival were
older age (.20 years), conditioning without ATG,
and a long (.3 years) interval from diagnosis to trans-
plant. The American Seattle study [29] tested different
doses of total body irradiation (TBI) and found that
2 Gywas the best dose.TheEBMTgroup tested a non-
radiation-based program: results were overall encour-
aging with 70% surviving, although rejection was
high in young adults over the age of 14 years. The
EBMT is currently testing a conditioning regimen
that is very similar to the Japanese regimen: Flu-
Cy-ATG and low-dose TBI (2 Gy) (unpublished). As
a consequence of less toxic conditioning regimens
and improved donor/recipient matching, survival has
almost doubled in the past decade [2,28] from 38% in
1991 to 1996 to 65% in the period 1997 to 2002, and
in the latter period survival afterUDtransplants in chil-
dren is 75% versus 63% for adults .16 years of age.
Results of UD transplants have improved to such an
extent, that treatment strategy may be affected: in chil-
dren without a matched sibling donor, a UD search
should be started at diagnosis, and transplantation
should be seriously considered after 1 course of IS in
the presence of a suitable donor. In young adults be-
tween 20 and 30 years old, the samemay be true. Adults
over the age of 30 years should be entered on a prospec-
tive trial, alternative donor transplant is an option for
second line treatment in patients failing 1 or 2 courses
of immunosuppressive treatment.Cord Blood Transplants
A proportion of patients will not have a matched
donor in the family, and will not find a suitable unre-
lated donor in the world-wide network (Bone Marrow
Donors World wide, BMDWW). The percentage of
patients who lack a donor will vary between 5% and
40%, according to the ethnic origin of the patient.
Cord blood transplantation (CBT) is an alternative
option that has been successfully explored in patients
with hematologic malignancies. Because of the high
rate of rejection in AA patients and the low cell num-
bers of CB units, transplants of unrelated CB have
been usually been discouraged in this setting. How-
ever, a recent study from the Japanese group [3] re-
ports 31 CBT with an OS of 42%, but a more
encouraging 80% survival for patients receiving the
Flu-Cy-TBI 2 Gy combination as a conditioningregimen. Thus, CB may not be the first option in AA
patients lacking a family donor, but some investigators
are exploring this stem cell source, and results may be
encouraging with appropriate cell dosing, double units
[31], alternative routes of administration, namely in-
traosseous, and new conditioning regimens [3].Conclusions
Children grafted from HLA-identical siblings
should receive a conventional CY200 conditioning
regimen, followed by BM as a stem cell source and
CsA plus MTX for GVHD prophylaxis. Adults,
grafted from HLA-identical siblings, may explore the
use of Flu-Cy with ATG. Patients who lack an HLA-
identical sibling should be considered for an alterna-
tive donor transplant: an 8/8 matched unrelated donor
would be the first choice, although it may be possible
to use also a 7/8 donor or a 1 antigen mismatched
family donor. The preferred conditioning regimen
for alternative donor transplants is Flu-Cy ATG with
the addition of low-dose (2 Gy) TBI. Young children
with an 8/8 matched UD may also be grafted with
Flu-Cy-ATG without TBI. The use of unrelated CB
remains investigational.ACKNOWLEDGMENTS
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